|
Gene: MED31 |
Gene summary for MED31 |
Gene summary. |
Gene information | Species | Human | Gene symbol | MED31 | Gene ID | 51003 |
Gene name | mediator complex subunit 31 | |
Gene Alias | 3110004H13Rik | |
Cytomap | 17p13.1 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9Y3C7 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51003 | MED31 | LZE3D | Human | Esophagus | HGIN | 4.39e-03 | 4.74e-01 | 0.0668 |
51003 | MED31 | LZE4T | Human | Esophagus | ESCC | 2.97e-09 | 2.87e-01 | 0.0811 |
51003 | MED31 | LZE7T | Human | Esophagus | ESCC | 1.09e-04 | 2.72e-01 | 0.0667 |
51003 | MED31 | LZE8T | Human | Esophagus | ESCC | 5.63e-07 | 2.56e-01 | 0.067 |
51003 | MED31 | LZE20T | Human | Esophagus | ESCC | 3.80e-07 | 1.70e-01 | 0.0662 |
51003 | MED31 | LZE22T | Human | Esophagus | ESCC | 9.07e-09 | 3.29e-01 | 0.068 |
51003 | MED31 | LZE24T | Human | Esophagus | ESCC | 2.64e-18 | 5.58e-01 | 0.0596 |
51003 | MED31 | LZE6T | Human | Esophagus | ESCC | 7.85e-06 | 2.99e-01 | 0.0845 |
51003 | MED31 | P2T-E | Human | Esophagus | ESCC | 1.37e-17 | 2.55e-01 | 0.1177 |
51003 | MED31 | P4T-E | Human | Esophagus | ESCC | 6.92e-38 | 8.81e-01 | 0.1323 |
51003 | MED31 | P5T-E | Human | Esophagus | ESCC | 1.88e-21 | 3.79e-01 | 0.1327 |
51003 | MED31 | P8T-E | Human | Esophagus | ESCC | 1.71e-29 | 4.77e-01 | 0.0889 |
51003 | MED31 | P9T-E | Human | Esophagus | ESCC | 2.87e-18 | 3.62e-01 | 0.1131 |
51003 | MED31 | P10T-E | Human | Esophagus | ESCC | 1.60e-22 | 3.18e-01 | 0.116 |
51003 | MED31 | P11T-E | Human | Esophagus | ESCC | 9.57e-12 | 5.94e-01 | 0.1426 |
51003 | MED31 | P12T-E | Human | Esophagus | ESCC | 2.58e-20 | 2.50e-01 | 0.1122 |
51003 | MED31 | P15T-E | Human | Esophagus | ESCC | 1.12e-11 | 2.80e-01 | 0.1149 |
51003 | MED31 | P16T-E | Human | Esophagus | ESCC | 1.75e-24 | 3.47e-01 | 0.1153 |
51003 | MED31 | P17T-E | Human | Esophagus | ESCC | 1.97e-08 | 4.49e-01 | 0.1278 |
51003 | MED31 | P19T-E | Human | Esophagus | ESCC | 9.09e-04 | 7.24e-01 | 0.1662 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004814414 | Esophagus | ESCC | fibroblast proliferation | 57/8552 | 81/18723 | 5.83e-06 | 6.03e-05 | 57 |
GO:004814514 | Esophagus | ESCC | regulation of fibroblast proliferation | 56/8552 | 80/18723 | 9.08e-06 | 8.71e-05 | 56 |
GO:00487367 | Esophagus | ESCC | appendage development | 98/8552 | 172/18723 | 1.83e-03 | 8.37e-03 | 98 |
GO:00601737 | Esophagus | ESCC | limb development | 98/8552 | 172/18723 | 1.83e-03 | 8.37e-03 | 98 |
GO:00481471 | Esophagus | ESCC | negative regulation of fibroblast proliferation | 22/8552 | 30/18723 | 1.98e-03 | 8.90e-03 | 22 |
GO:00481446 | Oral cavity | OSCC | fibroblast proliferation | 49/7305 | 81/18723 | 7.27e-05 | 5.72e-04 | 49 |
GO:00481457 | Oral cavity | OSCC | regulation of fibroblast proliferation | 48/7305 | 80/18723 | 1.14e-04 | 8.35e-04 | 48 |
GO:004814413 | Oral cavity | LP | fibroblast proliferation | 32/4623 | 81/18723 | 2.24e-03 | 1.62e-02 | 32 |
GO:004814513 | Oral cavity | LP | regulation of fibroblast proliferation | 31/4623 | 80/18723 | 3.69e-03 | 2.44e-02 | 31 |
GO:004814422 | Skin | cSCC | fibroblast proliferation | 38/4864 | 81/18723 | 3.88e-05 | 4.17e-04 | 38 |
GO:004814522 | Skin | cSCC | regulation of fibroblast proliferation | 37/4864 | 80/18723 | 7.15e-05 | 6.87e-04 | 37 |
GO:004814721 | Skin | cSCC | negative regulation of fibroblast proliferation | 15/4864 | 30/18723 | 4.07e-03 | 2.16e-02 | 15 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MED31 | SNV | Missense_Mutation | c.355T>A | p.Leu119Met | p.L119M | Q9Y3C7 | protein_coding | tolerated(0.29) | probably_damaging(0.969) | TCGA-AA-3867-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD | |
MED31 | SNV | Missense_Mutation | c.143N>C | p.Phe48Ser | p.F48S | Q9Y3C7 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
MED31 | SNV | Missense_Mutation | rs778765933 | c.133N>T | p.Asp45Tyr | p.D45Y | Q9Y3C7 | protein_coding | deleterious(0) | probably_damaging(0.914) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
MED31 | SNV | Missense_Mutation | novel | c.281N>T | p.Ala94Val | p.A94V | Q9Y3C7 | protein_coding | tolerated(0.13) | benign(0.184) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MED31 | SNV | Missense_Mutation | novel | c.335N>A | p.Arg112Gln | p.R112Q | Q9Y3C7 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MED31 | SNV | Missense_Mutation | novel | c.281N>T | p.Ala94Val | p.A94V | Q9Y3C7 | protein_coding | tolerated(0.13) | benign(0.184) | TCGA-A5-A0GG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MED31 | SNV | Missense_Mutation | novel | c.157A>G | p.Lys53Glu | p.K53E | Q9Y3C7 | protein_coding | deleterious(0.03) | benign(0.271) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MED31 | SNV | Missense_Mutation | novel | c.341G>A | p.Arg114His | p.R114H | Q9Y3C7 | protein_coding | deleterious(0) | probably_damaging(0.94) | TCGA-EY-A1G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MED31 | SNV | Missense_Mutation | novel | c.254N>A | p.Arg85Gln | p.R85Q | Q9Y3C7 | protein_coding | deleterious(0) | probably_damaging(0.936) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MED31 | SNV | Missense_Mutation | novel | c.10N>A | p.Ala4Thr | p.A4T | Q9Y3C7 | protein_coding | tolerated(0.4) | benign(0.018) | TCGA-85-A4JB-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | unknown | CR |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |